Oblique Therapeutics. We focus on developing new antibody medicines in pain and aggressive-metastatic cancer.
Investors 3
Date | Name | Website |
- | Almi Inves... | almi.se |
- | Midroc New... | midroc.se |
- | Stockholms... | stoaf.se |
Mentions in press and media 7
Date | Title | Description | Source |
28.11.2023 | AAX Biotech forms strategic collaboration with Oblique Thera... | AAX Biotech forms strategic collaboration with Oblique Therapeutics for therapeutic antibody develop... | news.cisio... |
09.11.2022 | Oblique Therapeutics is delighted to announce the appointmen... | Oblique Therapeutics is delighted to announce the appointment of Christer Nordstedt M.D. PhD . as Ch... | news.cisio... |
14.01.2022 | Oblique Therapeutics is pleased to announce that the United ... | Oblique Therapeutics is pleased to announce that the United States Patent and Trademark Office has g... | news.cisio... |
15.11.2021 | Oblique Therapeutics is thrilled to strengthen its commercia... | Oblique Therapeutics is thrilled to strengthen its commercial teams to realize its ambitious goals M... | news.cisio... |
14.10.2021 | Oblique Therapeutics is excited to present the recent progre... | Oblique Therapeutics is excited to present the recent progress on its anti-Thioredoxin mAb program a... | news.cisio... |
27.09.2021 | Oblique Therapeutics announces achievement of key milestone ... | Oblique Therapeutics announces achievement of key milestone in its aKRAS-mAb program and Abiprot® pl... | news.cisio... |
- | Targovax and Oblique enter collaboration to target mutant RA... | Oslo, Norway, & Gothenburg, Sweden 29 June 2020 – Targovax ASA (OSE: TRVX), a clinical stage imm... | healthcap.... |